Antihypertensive efficacy and tolerability of candesartan-hydrochlorothiazide 32/12.5 mg and 32/25 mg in patients not optimally controlled with candesartan monotherapy

Blood Pressure

Volumn 17, Issue SUPPL. 2, 2008, Pages 22-30

  Bönner, Gerd ^a   Balparda, C ^b   Cuneo, C ^b   Rojas, C ^b   Jure, H ^b   Luquez, H ^b   Montana O ^b   Salomone, O ^b   Rodenas, P ^b   Aizenberg, D ^b   Lecocq, L ^b   Saint Lannes, M ^b   Guerin, P ^b   Jourde, P ^b   Frohn, M ^b   Richter, D ^b   Leyendecker, P ^b   Cantin, T ^b   Smila, D ^b   Aim, L ^b   Combet, G ^b   Bertrand, G ^b   Lalanne, G ^b   Dammann, H G ^b   Radermacher, E ^b   Strotmann, H J ^b   Muenter, K C ^b   Daut, W ^b   Chevts, J ^b   Krause, G ^b   Andreas, K ^b   Hanefeld, M ^b   Naumburger, A ^b   Maus, O ^b   Fiesselmann, A ^b   Cama, R ^b   Karnad, D ^b   Thomas, M ^b   Vidyasagar, S ^b   Pedrinelli, R ^b   Perticone, M ^b   Mezzetti, A ^b   Bosi, S ^b   Di Biase, M ^b   Mayer, M ^b   Volpe, M ^b   Uguccioni, M ^b   Di Somma, S ^b   Santonastaso, M ^b   Rossi, P ^b   Glorioso, N ^b   Destro, M ^b   Mos, L ^b   Licata, G ^b   Donadon, V ^b   Locatelli, F ^b   Vinciguerra, A ^b   Sechi, L ^b   Aucello, G ^b   Gazzaruso, C ^b   Bryce, A ^b   Bustamante, G ^b   Cabrera, W ^b   Espinoza, J ^b   Heredia, J ^b   Horna, M ^b   Parra, J ^b   Toce, L ^b   Watanabe, L ^b   Kostenko, V ^b   Butko, D ^b   Svistov, A ^b   Shoustov, S ^b   Ershova, O ^b   Konrady, A ^b   Churina, S ^b   Yspenskiy, Y ^b   Petrov, A ^b   Espinel Garuz, E ^b   Pau, J ^b   Fluixa, C ^b   Calabuig, J ^b   Sipan, Y ^b   Comino, L ^b   Puig, J ^b   Mengual, L ^b   Perez, J ^b   Vinyoles, E ^b   more..

^a MEDIAN Kliniken GmbH   (Germany)

^b NONE

Author keywords

Candesartan cilexetil; Combination; Drug therapy; Hydrochlorothiazide; Hypertension; Randomized clinical trial

Indexed keywords

ANTIHYPERTENSIVE AGENT; CANDESARTAN HEXETIL; CANDESARTAN HEXETIL PLUS HYDROCHLOROTHIAZIDE; CHOLESTEROL; CREATININE; GLUCOSE; LIPID; POTASSIUM; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; URATE; ANGIOTENSIN RECEPTOR ANTAGONIST; BENZIMIDAZOLE DERIVATIVE; CANDESARTAN; DIURETIC AGENT; HYDROCHLOROTHIAZIDE; TETRAZOLE DERIVATIVE;

ADULT; AGED; ARTICLE; BLOOD PRESSURE REGULATION; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; FEMALE; GLUCOSE BLOOD LEVEL; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTENSION; HYPOTENSION; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; MONOTHERAPY; MORNING DOSAGE; MULTICENTER STUDY; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE BLIND PROCEDURE; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; URIC ACID BLOOD LEVEL; BLOOD PRESSURE; COMPARATIVE STUDY; DRUG COMBINATION; DRUG EFFECT; DRUG RESISTANCE; MIDDLE AGED; PATHOPHYSIOLOGY; TREATMENT OUTCOME;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BLOOD PRESSURE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; MALE; MIDDLE AGED; TETRAZOLES; TIME FACTORS; AGED, 80 AND OVER; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; DIURETICS; DRUG RESISTANCE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 57949116276     PISSN: 08037051     EISSN: 16511999     Source Type: Journal    
DOI: 10.1080/08038020802519220     Document Type: Article

References (19)

1. Guidelines Subcommittee (1999) 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens, 17, pp. 151-183.
2. Mancia, G., De Backer, G., Dominiczak, A., Cifkova, R., Fagard, R. Germano, G. et al. (2007) 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens, 25, pp. 1105-1187.
3. Chobanian, A. V., Bakris, G. L., Black, H. R., Cushman, W. C., Green, L. A. Izzo Jr, J. L. et al. (2003) The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 Report. JAMA, 289, pp. 2560-2572.
4. Hansson, L., Zanchetti, A., Carruthers, S. G., Dahlof, B., Elmfeldt, D. Julius, S. et al. (1998) Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet, 351, pp. 1755-1762.
5. Easthope, S. E. and Jarvis, B. (2002) Candesartan cilexetil-An update of its use in essential hypertension. Drugs, 62, pp. 1253-1287.
6. Elmfeldt, D., Olofsson, B. and Meredith, P. (2002) The relationships between dose and antihypertensive effect of four AT1-receptor blockers. Differences in potency and efficacy. Blood Pressure, 11, pp. 293-301.
7. Neutel, J. M. (1996) Metabolic manifestations of low-dose diuretics. Am J Med, 101, pp. 71S-82S.
8. Ramsay, L. E., Yeo, W. W., Chadwick, I. G. and Jackson, P. R. (1994) Diuretics. Textbook of hypertension, Blackwell Scientific Publications, Oxford
9. Melian, E. B. and Jarvis, B. (2002) Candesartan cilexetil plus hydrochlorothiazide combination - A review of its use in hypertension. Drugs, 62, pp. 787-816.
10. Philipp, T., Letzel, H. and Arens, H-J. (1997) Dose-finding study of candesartan cilexetil plus hydrochlorothiazide in patients with mild to moderate hypertension. J Hum Hypertens, 11, pp. S67-S68.
11. Papademetriou, V., Reif, M., Henry, D., Neutel, J. M., Levine, J. H. Hardison, J. D. et al. (2000) Combination therapy with candesartan cilexetil and hydrochlorothiazide in patients with systemic hypertension. J Clin Hypertens, 2, pp. 372-378.
12. Campbell, M., Sonkodi, S., Soucek, M. and Wiecek, A. (2001) A candesartan cilexetil/hydrochlorothiazide combination tablet provides effective blood pressure control in hypertensive patients inadequately controlled on monotherapy. Clin Exp Hypertens, 23, pp. 345-355.
13. Ohman, K. P., Milon, H. and Valnes, K. (2000) Efficacy and tolerability of a combination tablet of candesartan cilexetil and hydrochlorothiazide in insufficiently controlled primary hypertension-Comparison with a combination of losartan and hydrochlorothiazide. Blood Press, 9, pp. 214-220.
14. Koenig, W. (2000) Comparison of the efficacy and tolerability of combination tablets containing candesartan cilexetil and hydrochlorothiazide or losartan and hydrochlorothiazide in patients with moderate to severe hypertension. Results of the CARLOS-Study. Clin Drug Invest, 19, pp. 239-246.
15. The Heart Outcomes Prevention Evaluation (HOPE) Study Investigators (2000) Effect of angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med, 342, pp. 145-153.
16. Gleim, G. W., Rubino, J., Zhang, H., Shahinfar, S., Soffer, B. A. Lyle, P. A. et al. (2006) A multicenter, randomized, double-blind, parallel-group trial of the antihypertensive efficacy and tolerability of a combination of once-daily losartan 100 mg/hydrochlorothiazide 12.5 mg compared with losartan 100-mg monotherapy in the treatment of mild to severe essential hypertension. Clin Ther, 28, pp. 1639-1648.
17. Pool, J. L., Glazer, R., Weinberger, M., Alvarado, R., Huang, J. and Graff, A. (2007) Comparison of valsartan/hydrochlorothiazide combination therapy at doses up to 320/25 mg versus monotherapy: A double-blind, placebo-controlled study followed by long-term combination therapy in hypertensive adults. Clin Ther, 29, pp. 61-73.
18. Lacourciere, Y., Tytus, R., O'Keefe, D., Lenis, J., Orchard, R. and Martin, K. (2001) Efficacy and tolerability of a fixed-dose combination of telmisartan plus hydrochlorothiazide in patients uncontrolled with telmisartan monotherapy. J Hum Hypertens, 15, pp. 763-770.
19. Tuomilehto, J., Tykarski, A., Baumgart, P., Reimund, B., Breton, S. Le and Ferber, P. (2008) Combination therapy with valsartan/ hydrochlorothiazide at doses up to 320/25 mg improves blood pressure levels in patients with hypertension inadequately controlled by valsartan 320 mg monotherapy. Blood Press, pp. 15-23.